Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...
Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...
Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...
Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on ...
Five University of Cambridge experts have shared their views on whether semaglutide-based drugs like Wegovy and Ozempic can ...
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Ever since their rise in popularity as weight loss drugs, there’s been a slew of reports on the potential adverse health ...
GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback